Rivercell's €22M Bet: Build the Lab Before the Model
The Paris startup's €22 million seed is a bet on interventional data, not model architecture. A $1.8 billion public programme next door is financing the open alternative.
Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
The Paris startup's €22 million seed is a bet on interventional data, not model architecture. A $1.8 billion public programme next door is financing the open alternative.
ImPact Biotech's padeliporfin VTP cuts off a pancreatic tumour's blood supply from inside its feeding artery. Nine of 12 patients in a Phase 1 dose-escalation study reached surgery, and more than half of the resected tumours had clear margins. The trial is small, unblinded and years from a filing.
Warp Sciences emerged from stealth with $215 million at an $865 million valuation to build a US chemistry contract research organization. The investment case rests on a physical bottleneck: someone still has to make and test the molecules.
CereGate's Series C is a bet on the installed base: software that turns Boston Scientific deep brain stimulation generators into a walking cue for Parkinson's patients. The 41-patient US trial is open-label, has no control arm, and will not report until 2027.
Argenx sold $1.72 billion of Vyvgart in the third quarter, up 54% from a year earlier. Operating profit came in $80 million below consensus, and the Sjogren's failure leaves a $4 billion cost base betting on a bought pipeline.
A New York techbio company emerged from stealth with the largest phenotypic model it knows of, an 80% hit rate on five compounds, and one paying pilot. What the evidence supports, and what it does not.
Microbiotica's £36 million Series C buys a Phase 2 in ulcerative colitis, where a 63.2% remission signal from 29 patients now has to survive the endpoint that broke two rivals.
Nouscom closed a €120M Series D for NOUS-209, a vaccine designed to stop cancer before it forms in Lynch syndrome carriers. The evidence is immune response in 45 people, not a fall in cancer incidence. The registration trial will decide which of those two things investors own.